Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients

被引：2

作者：

Ferrucci, Silvia ^{[1
]}

Tavecchio, Simona ^{[1
]}

Maronese, Carlo Alberto ^{[1
,2
]}

Balato, Anna

Di Brizzi, Eugenia Veronica ^{[3
]}

Ortoncelli, Michela ^{[4
]}

Ribero, Simone ^{[4
]}

Girolomoni, Giampiero ^{[5
]}

Maurelli, Martina ^{[5
]}

Fortina, Anna Belloni ^{[6
]}

Caroppo, Francesca ^{[6
]}

Naldi, Luigi ^{[7
,8
]}

Pezzolo, Elena ^{[8
]}

Nettis, Eustachio ^{[9
]}

Pugliese, Francesco ^{[9
]}

Stingeni, Luca ^{[10
]}

Hansel, Katharina ^{[10
]}

Rubegni, Giovanni ^{[11
]}

Calabrese, Laura ^{[12
]}

Russo, Filomena ^{[13
]}

Gola, Massimo ^{[14
]}

Magnaterra, Elisabetta ^{[14
]}

Rongioletti, Franco ^{[15
]}

Mercuri, Santo Raffaele ^{[15
]}

Paolino, Giovanni ^{[15
]}

Savoia, Paola ^{[16
,17
]}

Veronese, Federica ^{[17
]}

Foti, Caterina ^{[18
]}

Ambrogio, Francesca ^{[19
]}

Scalvenzi, Massimiliano ^{[20
]}

Napolitano, Maddalena

Patruno, Cataldo ^{[21
]}

Dastoli, Stefano ^{[21
]}

Corazza, Monica ^{[22
]}

Borghi, Alessandro ^{[22
]}

Calzavara-Pinton, Pier Giacomo ^{[23
]}

Rossi, Mariateresa ^{[23
]}

Offidani, Annamaria ^{[24
]}

Radi, Giulia ^{[24
]}

Bonzano, Laura ^{[25
]}

Ferreli, Caterina ^{[26
]}

Piras, Viviana ^{[26
]}

Satta, Rosanna ^{[27
]}

Sucato, Federica ^{[27
]}

Malagoli, Piergiorgio ^{[28
]}

Gaiani, Francesca ^{[28
]}

Micali, Giuseppe ^{[29
]}

Musumeci, Maria Letizia ^{[29
]}

Fargnoli, Maria Concetta ^{[30
]}

Esposito, Maria ^{[31
]}

机构：

[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dermatol Unit, Milan, Italy

[2] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy

[3] Univ Campania Luigi Vanvitelli, Dermatol Unit, Naples, Italy

[4] Univ Turin, Med Sci Dept, Dermatol Clin, Turin, Italy

[5] Univ Verona, Dept Med, Sect Dermatol, Verona, Italy

[6] Univ Padua, Dept Women & Children Hlth, Padua, Italy

[7] Italian Grp Epidemiol Res Dermatol, Study Ctr, Bergamo, Italy

[8] San Bortolo Hosp Vicenza, Dept Dermatol, Vicenza, Italy

[9] Univ Bari, Sch & Chair Allergol & Clin Immunol, Dept Emergency & Organ Transplantat, Bari, Italy

[10] Univ Perugia, Dept Med, Sect Dermatol, Perugia, Italy

[11] Univ Siena, Dept Ophthalmol, Siena, Italy

[12] Univ Siena, Dept Med Sci Surg & Neurosci, Sect Dermatol, Siena, Italy

[13] IDI IRCCS, Ist Dermopat Immacolata, Rome, Italy

[14] Azienda Sanit & Univ Florence, Piero Palagi Hosp, Sect Dermatol, Viale Michelangiolo, Florence, Italy

[15] IRCCS San Raffaele Hosp, Dermatol Clin, Milan, Italy

[16] Univ Piemonte Orientale, Dept Hlth Sci, Novara, Italy

[17] AOU Maggiore della Carita Novara, Novara, Italy

[18] Univ Bari, Dept Dermatol, Dipartimento Sci Biomed & Oncol Umana, Bari, Puglia, Italy

[19] Univ Bari, Dept Precis & Regenerat Med & Ionian Area DiMePRe, Sect Dermatol & Venereol, Bari, Italy

[20] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy

[21] Magna Graecia Univ Catanzaro, Catanzaro, Calabria, Italy

[22] Univ Ferrara, Dept Med Sci, Sect Dermatol, Ferrara, Emilia Romagna, Italy

[23] Univ Brescia, Dermatol Dept, Brescia, Italy

[24] Univ Politecn Marche, Dept Clin & Surg Specialties, Fac Med & Chirurg, Ancona, Marche, Italy

[25] AUSL Modena, Allergol Serv, Modena, Italy

[26] Univ Cagliari, Dept Med Sci & Publ Hlth, Unit Dermatol, Cagliari, Italy

[27] Univ Sassari, Dept Med Surg & Expt Sci, Dermatol Unit, Sassari, Italy

[28] Ist Policlin San Donato, Milan, Italy

[29] Univ Catania, Catania, Italy

[30] Univ Aquila, Dept Dermatol, Laquila, Italy

[31] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[32] Univ Rome Sapienza, Dermatol Unit, Rome, Italy

[33] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy

来源：

CLINICAL AND EXPERIMENTAL DERMATOLOGY | 2024年 / 49卷 / 12期

关键词：

EUROPEAN GUIDELINES; ADULTS; MANAGEMENT; PLACEBO;

D O I：

10.1093/ced/llae208

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background The efficacy and safety of dupilumab in atopic dermatitis (AD) have been defined in clinical trials but limited real-world evidence on long-term treatment outcomes is currently available to inform clinical decisions. Objectives To describe the long-term effectiveness and safety of dupilumab up to 48 months in patients with moderate-to-severe AD. Methods A multicentre, retrospective, dynamic cohort study was conducted to assess long-term effectiveness and safety of dupilumab in patients with moderate-to-severe AD in a real-world setting. Predictors of minimal disease activity (MDA) optimal treatment target criteria [defined as the simultaneous achievement of a 90% reduction in Eczema Area and Severity Index score, itch-numeric rating scale (NRS) score <= 1, sleep-NRS score <= 1 and Dermatology Life Quality Index <= 1] were investigated. Results In total, 2576 patients were enrolled from June 2018 to July 2022. MDA optimal treatment target criteria were achieved by 506/2309 (21.9%), 769/1959 (39.3%), 628/1247 (50.4%), 330/596 (55.4%) and 58/106 (54.7%) of those that reached 4, 12, 24, 36 and 48 months of follow-up, respectively. Logistic regression revealed a negative effect on MDA achievement for conjunctivitis and food allergy at all timepoints. Adverse events (AEs) were mild and were observed in 373/2364 (15.8%), 166/2066 (8.0%), 83/1291 (6.4%), 27/601 (4.5%) and 5/110 (4.5%) of those that reached 4, 12, 24, 36 and 48 months of follow-up. Conjunctivitis was the most frequently reported AE during the available follow-up. AEs led to treatment discontinuation in < 1% of patients during the evaluated time periods. Conclusions The high long-term effectiveness and safety of dupilumab were confirmed in this dynamic cohort of patients with moderate-to-severe AD, regardless of clinical phenotype and course (persisting or relapsing) at baseline. Further research will be needed to investigate the effect of T helper cell 2 comorbidities and disease duration on the response to dupilumab and other newer therapeutics for AD.

引用

页码：1561 / 1572

页数：12

共 50 条

[31] Real-world efficacy and safety of dupilumab for paediatric atopic dermatitis: a multicentre retrospective study
Pirov, Eitan
Molho-Pessach, Vered
Cohen-Barak, Eran
Levitt, Jen A. Barak
Barzilai, Aviv
Bar, Jonathan
Renert-Yuval, Yael
Bar-Ilan, Efrat
Friedland, Rivka
Greenberger, Shoshana
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024,
[32] Dupilumab provides long-term improvement in pruritus in children with severe atopic dermatitis and adolescents and adults with moderate-to-severe atopic dermatitis
Cork, Michael J.
Yosipovitch, Gil
Silverberg, Jonathan I.
Praestgaard, Amy
Zhang, Haixin
Wang, Zhixiao
Rossi, Ana B.
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 79 - 79
[33] Effectiveness of abrocitinib for the treatment of moderate-to-severe atopic dermatitis in patients switched from dupilumab and/or tralokinumab: A real-world retrospective study
Keow, Samantha
Abu-Hilal, Mohannad
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 91 (04) : 734 - 735
[34] Effectiveness and safety of dupilumab in moderate-to-severe atopic dermatitis patients with chronic renal insufficiency: a real-world retrospective study in China
Peng, Cong
Cao, Qiaozhi
Xiong, Feng
Xu, Hui
Li, Jie
MEDCOMM, 2024, 5 (10):
[35] Real-life long-term efficacy of dupilumab in adults with moderate to severe atopic dermatitis: Results of a cohort study
Guedon, C.
Tauber, M.
Linder, C.
Paul, C.
Shourick, J.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2023, 150 (03): : 215 - 216
[36] Effectiveness and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: a preliminary report of real-world data
Ferrucci, Silvia M.
Maronese, Carlo A.
Tavecchio, Simona
Angileri, Luisa
Genovese, Giovanni
Marzano, V. Angelo
ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2022, 157 (02) : 211 - 213
[37] Long-term, observational, real-world study of dupilumab for the treatment of moderate-to-severe atopic dermatitis: a 52-week single-center retrospective analysis in China
Deng, Sisi
Wang, Huan
Chen, Qiquan
Chen, Xueqin
Song, Xiao
Chen, Shuguang
Kong, Minmin
Song, Zhiqiang
ARCHIVES OF DERMATOLOGICAL RESEARCH, 2024, 316 (06)
[38] Real-World Experience of Long-Term Dupilumab Treatment for Atopic Dermatitis in Korea
Lee, Dong Hun
Ko, Hyun Chang
Na, Chan Ho
Roh, Joo Young
Park, Kui Young
Park, Young Lip
Park, Young Min
Park, Chang Ook
Park, Chun Wook
Bae, Youin
Seo, Young-Joon
Son, Sang Wook
Ahn, Jiyoung
Jung, Hye Jung
Yang, Jun-Mo
Won, Chong Hyun
Yoo, Kwang Ho
Lew, Bark Lynn
Lee, Sang Eun
Lee, Sung Yul
Lee, Seung-Chul
Lee, Yang Won
Lee, Ji Hyun
Jang, Yong Hyun
Jeon, Jiehyun
Han, Tae-Young
Cho, Sang Hyun
ANNALS OF DERMATOLOGY, 2022, 34 (02) : 157 - 160
[39] PATIENT PERCEPTION OF TREATMENT WITH LONG-TERM DUPILUMAB MONOTHERAPY IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
Simpson, E.
Lacour, J.
Beck, L.
Zhang, H.
Aamodt, K.
Rossi, A.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S55 - S56
[40] PHARMACOKINETICS OF DUPILUMAB IN LONG-TERM PHASE III STUDIES IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS.
Davis, J. D.
Rawal, S.
Kamal, M.
Li, M.
Lai, C. -H.
Ardeleanu, M.
DiCioccio, A. T.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S61 - S61

← 1 2 3 4 5 →